Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers

Phase 1CompletedNCT01204112

Pfizer12 enrolled

Overview

The current study is designed to estimate the effect of rifampin (600 mg orally every 24 hours for 7 days) on pharmacokinetics of single 30 mg dose (CP-690,550) in normal healthy volunteers

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

Tasocitinib (CP-690,550) plus RifampinDRUG

Period 1, Day 1: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 1-7: Rifampin 600 mg (single oral dose) q24h Period 2, Day 8: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 9: No treatment (discharge)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy male and/or female subjects (of non-childbearing potential) Exclusion Criteria: * Clinically significant disease or condition * Recent serious infection

Locations (1)

Pfizer Investigational Site

New Haven, Connecticut, United States

Outcomes

Primary Outcomes

AUCinf of tasocitinib (CP-690,550)

Time frame: 9 days

Cmax of tasocitinib (CP-690,550)

Time frame: 9 days

Secondary Outcomes

AUClast, Tmax, t1/2 of tasocitinib (CP-690,550)

Time frame: 9 days

Safety: clinical laboratory abnormalities, AE reporting, and vital signs (blood pressure/pulse rate).

Time frame: 9 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.